✉news HealthFitness first seen 1 d ago, last 1 d ago, peak #33
CSL signs drug deal with Swiss biotech giant to fight rare disease
Australian biotech CSL has signed a drug development agreement with a Swiss biotech company to develop a treatment for a rare disease. The deal pairs CSL's global plasma and therapeutics scale with the Swiss firm's early-stage pipeline, and marks another step in CSL's push to expand beyond its core blood products business into rare and serious conditions.
Why now: CSL is a major Australian biotech and any major new drug partnership attracts attention in healthcare and investment circles
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/1052922